Referring to the information, published at the news portal BNS, JSC “Grindeks” confirms that expansion of cooperation with the Latvian Institute of Organic Synthesis is being considered. With the aim to combine scientific work and the production of pharmaceuticals, JSC “Grindeks” would consider buying the Institute of Organic Synthesis, if such opportunity existed. On “Grindeks” “Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Product portfolio of “Grindeks” consists of original products, generics and active pharmaceutical ingredients. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. Group of “Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, the USA. JSC “Grindeks” shares are listed in the Official List of “NASDAQ OMX Riga”. Further information: Ilze Kreicmane Deputy Head of the Communications Department, JSC “Grindeks” Phones: (+371) 67083336, (+371) 26466681 Fax: (+371) 67083505 ilze.kreicmane@grindeks.lv